Although several such agents are currently in early stage clinical development [66], dasatinib is the most clinically advanced and is the only dual SFK/BCR-ABL inhibitor approved in the United States and Europe for the treatment of patients with imatinib-resistant or -intolerant CML and Ph+ ALL. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.